CAJ | 학술논문

目的探讨肝癌晚期患者采用干扰素辅助经导管肝动脉化疗栓塞(TACE)的治疗效果.方法将2011年2月至2012年8月确诊为病毒性肝炎肝癌晚期的96例患者.完全随机分为观察组和对照组,各48例.对照组患者多个常规TACE治疗；观察组患者在TACE基础上加用干扰素α皮下注射,(3～5) ×1010 IU/m2,1次/d.疗程均为8周.观察患者治疗前及治疗4、8周甲胎蛋白(AFP)水平,疗程结束后进行疗效评价.结果观察组治疗前和治疗4、8周后AFP分别为(446 ±89)、(101±55)、(70±28) μg/L,对照组分别为(452 ±91)、(151 ±44)、(112±32) μg/L.观察组治疗前AFP与对照组同期比较,差异无统计学意义(P＞0.05)；观察组治疗4、8周与对照组同期比较,差异有统计学意义(P＜0.05).观察组和对照组总有效率分别为95.8％ (46/48)、79.2％ (38/48),组间差异有统计学意义(P＜0.05).结论干扰素辅助TACE可以有效控制肝癌晚期患者AFP的增长,抑制肿瘤增长.
목적 탐토간암만기환자채용간우소보조경도관간동맥화료전새(TACE)적치료효과.방법 장2011년2월지2012년8월학진위병독성간염간암만기적96례환자.완전수궤분위관찰조화대조조,각48례.대조조환자다개상규TACE치료；관찰조환자재TACE기출상가용간우소α피하주사,(3～5) ×1010 IU/m2,1차/d.료정균위8주.관찰환자치료전급치료4、8주갑태단백(AFP)수평,료정결속후진행료효평개.결과 관찰조치료전화치료4、8주후AFP분별위(446 ±89)、(101±55)、(70±28) μg/L,대조조분별위(452 ±91)、(151 ±44)、(112±32) μg/L.관찰조치료전AFP여대조조동기비교,차이무통계학의의(P＞0.05)；관찰조치료4、8주여대조조동기비교,차이유통계학의의(P＜0.05).관찰조화대조조총유효솔분별위95.8％ (46/48)、79.2％ (38/48),조간차이유통계학의의(P＜0.05).결론 간우소보조TACE가이유효공제간암만기환자AFP적증장,억제종류증장.
Objective To explore the curative effect of interferon auxiliary transcatheter arterial chemoembolization(TACE) in treatment of advanced liver cancer patients.Methods From February 2011 to August 2012,96 patients of viral hepatitis in late liver cancer were enrolled in this study.All the patients were randomly divided into observation group and control group (48 cases in each group).Patients in control group were treated with TACE,patients in observation group were treated with TACE and interferon alpha subcutaneous injection[(3-5) ×1010 IU/m2].The effect evaluation and alpha fetoprotein(AFP) before treatment and after treatment in 4,8 weeks were observed.Results AFP in the observation group before treatment and after treatment in 4,8 weeks was (446 ± 89) μg/L,(101 ± 55) μg/L,(70 ± 28) μg/L; AFP in the control group were (452 ± 91) μg/L,(151 ± 44) μg/L,(112 ± 32) μg/L.There was no significant difference between observation group before treatment and control group(P ＞ 0.05).AFP in the observation group after treatment in 4,8 weeks was significantly lower than that in control group during the same period(P ＜0.05).Total effective rate in the observation group and the control group was 95.8％ (46/48) and 79.2％ (38/48) respectively; there was a statistically significant difference between the two groups (P＜0.05).Conclusion Interferon assisted TACE can effectively control AFP growth and tumor growth in the advanced liver cancer patients.